Who Paid My Doc
Azedra
Drug Radiopharmaceutical
NDC 71258-015-22
General payments
$225,932
Research payments
$469,682
Through program year 2024, $225,932 in general payments and $469,682 in research payments were reported against Azedra (Radiopharmaceutical).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
11 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $338 | 1 |
| 2024 | Research | $275,213 | 7 |
| 2023 | General | $32,272 | 19 |
| 2023 | Research | $106,260 | 5 |
| 2022 | General | $42,644 | 42 |
| 2022 | Research | $35,227 | 2 |
| 2021 | General | $13,541 | 6 |
| 2021 | Research | $46,953 | 4 |
| 2020 | General | $34,275 | 11 |
| 2020 | Research | $6,029 | 1 |
| 2019 | General | $102,863 | 11 |
Breakdown
Each share is of general payments naming this product in 2024.
Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2024 where a state was reported.
Records
90 general · 19 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.